Understanding how a coenzyme helps tuberculosis bacteria survive in humans
Coenzyme F420, helping mycobacteria find a niche in humans
['FUNDING_R21'] · ALBERT EINSTEIN COLLEGE OF MEDICINE · NIH-10666639
This study is looking at how a special helper called coenzyme F420 helps the tuberculosis bacteria survive in tough, low-oxygen environments, with the goal of finding new ways to treat people who have latent TB infections.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ALBERT EINSTEIN COLLEGE OF MEDICINE (nih funded) |
| Locations | 1 site (BRONX, UNITED STATES) |
| Trial ID | NIH-10666639 on ClinicalTrials.gov |
What this research studies
This research investigates the role of coenzyme F420 in the survival of Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB), particularly under low-oxygen conditions found in granulomas. By exploring how this coenzyme supports the bacteria's metabolism and helps it endure stress, the research aims to identify potential strategies to disrupt its persistence and treat latent TB infections. The study employs a combination of genetic analysis, metabolomics, animal models, and protein biology to gain insights into the mechanisms at play.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with latent tuberculosis infections or those at risk of developing TB.
Not a fit: Patients with active tuberculosis or those who do not have a history of TB exposure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively eliminate latent tuberculosis infections.
How similar studies have performed: Previous research has shown promise in targeting metabolic pathways in bacteria, suggesting that this approach could yield significant insights and advancements in TB treatment.
Where this research is happening
BRONX, UNITED STATES
- ALBERT EINSTEIN COLLEGE OF MEDICINE — BRONX, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BERNEY, MICHAEL — ALBERT EINSTEIN COLLEGE OF MEDICINE
- Study coordinator: BERNEY, MICHAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Disease